Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy

Junmeng Zhu(Nanjing Drum Tower Hospital), Baorui Liu(Nanjing University of Chinese Medicine)
Nature Communications
December 3, 2022
Cited by 102


Related Papers